Compare IQV & XYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | XYL |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 29.2B |
| IPO Year | 2013 | 2011 |
| Metric | IQV | XYL |
|---|---|---|
| Price | $168.96 | $129.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | ★ $227.13 | $155.55 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | 4.67 | ★ 7.40 |
| EPS | ★ 7.84 | 3.92 |
| Revenue | ★ $9,739,000,000.00 | $9,035,000,000.00 |
| Revenue This Year | $6.78 | $2.91 |
| Revenue Next Year | $5.88 | $4.51 |
| P/E Ratio | ★ $22.03 | $32.68 |
| Revenue Growth | ★ 41.60 | 5.52 |
| 52 Week Low | $134.65 | $105.73 |
| 52 Week High | $247.05 | $154.27 |
| Indicator | IQV | XYL |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 62.08 |
| Support Level | $159.42 | $123.98 |
| Resistance Level | $170.89 | $132.86 |
| Average True Range (ATR) | 6.19 | 2.92 |
| MACD | 1.31 | 1.51 |
| Stochastic Oscillator | 36.04 | 99.19 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.